Clinical Results with Direct Thrombin Inhibitors | Zendy

Andrew Nicolaides | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Results with Direct Thrombin Inhibitors

Author(s) -

Andrew Nicolaides

Publication year - 2002

Publication title -

pathophysiology of haemostasis and thrombosis

Language(s) - English

Resource type - Journals

eISSN - 1424-8840

pISSN - 1424-8832

DOI - 10.1159/000069107

Subject(s) - argatroban , discovery and development of direct thrombin inhibitors , thrombin , hirudin , direct thrombin inhibitor , heparin , medicine , antithrombin , pharmacology , fibrin , thrombosis , coagulation , low molecular weight heparin , warfarin , immunology , dabigatran , platelet , atrial fibrillation

Direct thrombin inhibitors inactivate thrombin without the need for antithrombin and some inactivate not only thrombin but also fibrin-bound thrombin. Hirudin has been shown to be more effective than low-dose unfractionated heparin and low molecular weight heparin for the prevention of deep vein thrombosis in high-risk orthopaedic patients. Major studies are assessing the value of direct thrombin inhibitors in patients with acute coronary syndromes. Currently, argatroban is the drug of choice in patients with heparin-induced thrombocytopenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research